Business
Stablepharma and AFT Pharmaceuticals (NZX: AFT; ASX: AFP) partner to address multi-billion dollar anti-infective and oncology therapeutics market
Stablepharma Ltd R&D Centre, Madrid, Spain Stablepharma and AFT Pharmaceuticals partner to address multi-billion dollar anti-infective and oncology therapeutics market LONDON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total g
About this update from Aft Pharmaceuticals Ltd.
[{"type":"image","alt":"Stablepharma Ltd","displaySize":"","headline":null,"caption":"Stablepharma Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3829ca48879f1659838db55559064379"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Vok.j8kkQ232cuNqMKbWGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3829ca48879f1659838db55559064379","width":300,"height":300}},"lazy":false},{"type":"text","content":"Stablepharma Ltd R&D Centre, Madrid, Spain","length":46,"tagName":"p"},{"type":"image","alt":"Stablepharma and AFT Pharmaceuticals partner to address multi-billion dollar anti-infective and oncology therapeutics market","displaySize":"","headline":null,"caption":"Stablepharma and AFT Pharmaceuticals partner to address multi-billion dollar anti-infective and oncology therapeutics market","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":5713,"height":3809,"url":"https://media.zenfs.com/en/globenewswire.com/e534e48c465471ab2ffeece2ba3cb04e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V1ym2fLxyUuTiGKb4iJyKA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e534e48c465471ab2ffeece2ba3cb04e","width":960,"height":640},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Mz3kLluN6junPj17ukXp4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xNjAwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/e534e48c465471ab2ffeece2ba3cb04e","width":1200,"height":800}}},{"type":"text","content":"LONDON, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Stablepharma Limited, specialists in thermostable formulations, today announced a development and option-to-license agreement with AFT Pharmaceuticals to develop a portfolio of fridge-free sterile injectable medicines, initially targeting anti-infective and oncology treatments in a total global market valued at over USD 6 billion.","length":374,"tagName":"p"},{"type":"text","content":"Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently require cold-chain storage. Stablepharma will be eligible to receive future milestone and royalty revenue from AFT upon commercialisation.","length":285,"tagName":"p"},{"ty...